Chimeric antigen receptor modified T-cells for cancer treatment
Chimeric antigen receptor modified T-cells for cancer treatment作者机构：Molecular & Immunological Department Bio-therapeutic Department The General Hospital of People''s Liberation Army Beijing China
出 版 物：《慢性疾病与转化医学(英文)》 (Chronic Diseases and Translational Medicine)
年 卷 期：2018年第04卷第04期
页 面：225-243页
核心收录：
学科分类：1002[医学-临床医学] 08[工学] 0805[工学-材料科学与工程（可授工学、理学学位）]
基 金：supported by the grants from the National Natural Science Foundation of China (No.81230061 to WDH) the Science and Technology Planning Project of Beijing City (No.Z151100003915076 to WDH) the National Key Research and Development Program of China (No.2016YFC1303501 and 2016YFC1303504 to WDH)
主 题：Chimeric antigen receptor T-cell Hematologic malignancies Solid tumor Toxicities
摘 要：T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), and a complete remission rate as high as 90% was observed, in both children and adults. Although the achievement of clinical efficacy using CAR-T cell therapy for solid tumors has encountered several obstacles that were associated with the multiple mechanisms contributing to an immunosuppressive microenvironment, investigators are exploring more optimized approaches to improve the efficiency of CAR-T in solid tumors. In addition, cytokine release syndrome (CRS) and neurotoxicity following CAR-T cell therapy can be severe or even fatal; therefore, the management of these toxicities is significant. Herein, we briefly review the structure of CAR-T and some novel CAR designs, the clinical application of CAR-T cell therapies, as well as the assessment and management of toxicities.
同方期刊数据库